Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could r...

Full description

Bibliographic Details
Main Authors: Cécile Hérate, Romain Marlin, Franck Touret, Nathalie Dereuddre-Bosquet, Flora Donati, Francis Relouzat, Laura Junges, Mathilde Galhaut, Océane Dehan, Quentin Sconosciuti, Antoine Nougairède, Xavier de Lamballerie, Sylvie van der Werf, Roger Le Grand
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Heliyon
Subjects:
SARS-CoV2
Sotrovimab
Non human primate
BQ.1.1
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023038719

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023038719

Similar Items